Tumor budding, EMT and cancer stem cells in T1-2/N0 oral squamous cell carcinomas

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 6111-6120

  Attramadal, Cecilie Gjøvaag ^a   Kumar, Sheeba ^a   Boysen, Morten E ^b   Dhakal, Hari Prasad ^b   Nesland, Jahn Martin ^b   Bryne, Magne ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

CSC; EMT; Oral squamous cell carcinoma; Prognosis; Tumor budding

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOFORM 1; ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CD24 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; HERMES ANTIGEN; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURGERY; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; ONCOLOGICAL PARAMETERS; PAN KERATIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR BUDDING; UPREGULATION; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME;

BIOMARKERS, TUMOR; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN; VIMENTIN;

EID: 84946058390     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45(4-5): 309-316, 2009.
2. http://emedicine.medscape.com/article/1075729-treatment#a1127
3. http://www.uicc.org/resources/tnm
4. Huang RY, Guilford P and Thiery JP: Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci 125(Pt 19): 4417-4422, 2012.
5. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2): 131-142, 2006.
6. Chen C, Zimmermann M, Tinhofer I, Kaufmann AM and Albers AE: Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 338(1): 47-56, 2013.
7. Tsai JH, Donaher JL, Murphy DA, Chau S and Yang J: Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22(6): 725-736, 2012.
8. Warrier S, Bhuvanalakshmi G, Arfuso F, Rajan G, Millward M and Dharmarajan A: Cancer stem-like cells from head and neck cancers are chemosensitized by the wnt antagonist, sfrp4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther 21(9): 381-388, 2014.
9. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM and Albers AE: Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 6(1): e16466, 2011.
10. Tarin D: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65(14): 5996-6000, 2005.
11. Papagerakis S, Pannone G, Zheng L, About I, Taqi N, Nguyen NP, Matossian M, McAlpin B, Santoro A, McHugh J, Prince ME and Papagerakis P: Oral epithelial stem cells-implications in normal development and cancer metastasis. Exp Cell Res 325(2): 111-129, 2014.
12. Azvolinsky A. Cancer Stem cells: Cancer's Roots. Oxford University Press 2012.
13. Major AG, Pitty LP and Farah CS: Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int 2013: 319489, 2013.
14. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G: Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J 27(1): 13-24, 2013.
15. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nature Reviews: Cancer 5: 744-749, 2005.
16. Brabletz T: To differentiate or not-routes towards metastasis. Nat Rev Cancer 12(6): 425-436, 2012.
17. Christofori G: New signals from the invasive front. Nature 441(7092): 444-450, 2006.
18. Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masuda D, Takeichi H, Kato N, Nakagawa T, Tanaka M, Inokuchi S and Iwazaki M: Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 6(5): 937-943, 2012.
19. Koelzer VH, Langer R, Zlobec I and Lugli A: Tumor budding in upper gastrointestinal carcinomas. Front Oncol 4: 216, 2014.
20. Lugli A, Karamitopoulou E and Zlobec I: Tumour budding: A promising parameter in colorectal cancer. Br J Cancer 106(11): 1713-1717, 2012.
21. Nilsson PJ, Rubio C, Lenander C, Auer G and Glimelius B: Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer. Ann Oncol 16(6): 893-898, 2005.
22. Brown M, Sillah K, Griffiths EA, Swindell R, West CM, Page RD, Welch IM and Pritchard SA: Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 56(7): 893-899, 2010.
23. Imai T: The growth of human carcinoma: A morphological analysis. Fukuoka Igaku Zasshi 45(30), 1954.
24. Mitrovic B, Schaeffer DF, Riddell RH and Kirsch R: Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol 25(10): 1315-1325, 2012.
25. Rogers AC, Gibbons D, Hanly AM, Hyland JM, O'Connell PR, Winter DC and Sheahan K: Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol 27(1): 156-162, 2014.
26. Niwa Y, Yamada S, Koike M, Kanda M, Fujii T, Nakayama G, Sugimoto H, Nomoto S, Fujiwara M and Kodera Y: Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. J Surg Oncol 110(6): 764-769, 2014.
27. Bryne M KH, Lilleng R and Kjaerheim A: Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 4(166): 375-381, 1992.
28. Brandwein-Gensler M, Texeira M, Lewis C, Lee B, Rolnitzky L, Hille J, Genden E, Urken M and Wang B: Oral squamous cell carcinoma: Histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29: 167-178, 2005.
29. Kawashiri S, Tanaka A, Noguchi N, Hase T, Nakaya H, Ohara T, Kato K and Yamamoto E: Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 31(10): 1346-1353, 2009.
30. Bánkfalvi A and Piffkó J: Prognostic and predictive factors in oral cancer: The role of the invasive tumour front. J Oral Pathol Med 29: 291-298, 2000.
31. Karamitopoulou E: Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol 2: 209, 2012.
32. Almangush A, Salo T, Hagstrom J and Leivo I: Tumour budding in head and neck squamous cell carcinoma-a systematic review. Histopathology, 2014.
33. Xie N, Wang C, Liu X, Li R, Hou J, Chen X and Huang H: Tumor budding correlates with occult cervical lymph node metastasis and poor prognosis in clinical early-stage tongue squamous cell carcinoma. J Oral Pathol Med 44(4): 266-272, 2015.
34. Manjula BV, Augustine S, Selvam S and Mohan AM: Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: Role of tumor budding and pattern of invasion. Indian J Otolaryngol Head Neck Surg 67: 98-104, 2015.
35. Attramadal CG, Halstensen TS, Dhakal HP, Ulekleiv CH, Boysen ME, Nesland JM and Bryne M: High nuclear sox2 expression is associated with radiotherapy response in small (t1/t2) oral squamous cell carcinoma. J Oral Pathol Med 44: 515-522, 2015.
36. Hamilton SR and Aaltonen LA: Who classification of tumours. Pathology and genetics of tumours of the digestive system. IARC, International Agency for Research on Cancer (IARC), Lyon, France, 2000.
37. Bryne M: Is the invasive front of an oral carcinoma the most important area for prognostication? Oral Diseases 4(2): 70-77, 1998.
38. Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, Zhou X and Liu X: Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 40(7): 545-551, 2011.
39. Almangush A, Bello IO, Keski-Santti H, Makinen LK, Kauppila JH, Pukkila M, Hagstrom J, Laranne J, Tommola S, Nieminem O, Soini Y, Kosma VM, Koivunen P, Grenman R, Leivo I and Salo T: Depth of invasion, tumor budding, and worst pattern of invasion: Prognostic indicators in early-stage oral tongue cancer. Head & Neck 36(6): 811-818, 2014.
40. Almangush A, Coletta RD, Bello IO, Bitu C, Keski-Santti H, Makinen LK, Kauppila JH, Pukkila M, Hagstrom J, Laranne J, Tommola S, Soini Y, Kosma VM, Koivunen P, Kowalski LP, Nieminen P, Grenman R, Leivo I and Salo T: A simple novel prognostic model for early stage oral tongue cancer. Int J Oral Maxillofac Surg 44(2): 143-150, 2015.
41. Zlobec I and Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget 1: 651-661, 2010.
42. van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A and McMillan DC: The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: A systematic review. Cancer Treat Rev 41(2): 151-159, 2015.
43. Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, Lugli A and Zlobec I: The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology 64(4): 577-584, 2014.
44. Smith A, Teknos TN and Pan Q: Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 49(4): 287-292, 2013.
45. Krisanaprakornkit S and Iamaroon A: Epithelial-mesenchymal transition in oral squamous cell carcinoma. ISRN Oncol 2012: 681469, 2012.
46. Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G and Psyrri A: Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (hnscc). PLoS One 9(4): e94273, 2014.
47. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S and Farah CS: Epithelial to mesenchymal transition (emt) biomarkers-ecadherin, beta-catenin, apc and vimentin-in oral squamous cell carcinogenesis and transformation. Oral Oncol 48(10): 997-1006, 2012.
48. Brabletz T, Jung A and Kirchner T: Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 441(1): 1-11, 2002.
49. Koontongkaew S: The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 4(1): 66-83, 2013.
50. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA and Reiter RE: Monoclonal antibody targeting of n-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16(12): 1414-1420, 2010.
51. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR: Cadherin switching. J Cell Sci 121(Pt 6): 727-735, 2008.
52. Nakagawa Y ea: Tumor budding and e-cadherin expression are useful predictors of nodal involvement in t1 esophageal squamous cell carcinoma. Anticancer Res 33: 5023-5030, 2013.
53. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH and Niederhuber JE: Complex display of putative tumor stem cell markers in the nci60 tumor cell line panel. Stem Cells 28(4): 649-660, 2010.
54. Patel SS, Shah KA, Shah MJ, Kothari KC and Rawal RM: Cancer stem cells and stemness markers in oral squamous cell carcinomas. Asian Pacific Journal of Cancer Prevention 15(20): 8549-8556, 2014.
55. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, Costea DE and Mackenzie IC: Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71(15): 5317-5326, 2011.